BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

NCT03083691 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Carcinoma, Small Cell Lung

Interventions

DRUG: Nivolumab, Ipilimumab
DRUG: Nivolumab, Ipilimumab

Sponsor

Lung Cancer Group Cologne

Collaborators

[object Object]